Welcome to our dedicated page for Algernon Pharmac news (Ticker: AGNPF), a resource for investors and traders seeking the latest updates and insights on Algernon Pharmac stock.
Algernon Pharmaceuticals Inc. (AGNPF) is a clinical-stage biopharmaceutical company advancing innovative therapies for neurological conditions through drug repurposing and clinical research. This news hub provides investors and industry observers with timely updates on the company's scientific progress and corporate developments.
Access comprehensive coverage of AGNPF's press releases, including clinical trial results, regulatory milestones, and strategic partnerships. The curated collection serves as a centralized resource for understanding the company's research initiatives in stroke treatment and neurodegenerative disorders.
Key updates feature developments related to NP-251 (Repirinast) and other pipeline candidates, alongside analysis of trial designs and scientific collaborations. Content is organized to highlight material events while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined access to Algernon Pharmaceuticals' official communications and third-party coverage. Regularly updated to reflect new developments in neuroscience research and biopharmaceutical innovation.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) has increased its non-brokered private placement from $250,000 to $408,000. The offering consists of units priced at $0.12, each comprising one common share and one purchase warrant. Warrants are exercisable at $0.24 per share for 2 years, subject to acceleration if the stock price exceeds $0.36 for 20 consecutive trading days. The closing date is set for August 1, 2024. Proceeds will be used for working capital. The company may pay cash finder's fees and issue finder's warrants up to 8% of the proceeds and units for introduced investors. Securities will have a 4-month hold period and are not registered under the U.S. Securities Act.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF) reports significant results from a study on ifenprodil for cough suppression. The multi-dose study, conducted by Seyltx, showed a 93% reduction in median cough count in guinea pigs. Seyltx, which acquired Algernon's ifenprodil research program for $2M USD and a 20% equity position, plans to begin patient enrollment for the SILINDA Phase 2b study in early 2025.
Ifenprodil, an NMDA receptor antagonist, achieved near-complete cough suppression at a 30 mg/kg dose. The upcoming SILINDA Phase 2b study will evaluate ifenprodil's efficacy in approximately 240 adults with refractory chronic cough (RCC), with expected treatment arms of 40 mg, 80 mg, and 120 mg TID. Topline data from SILINDA are anticipated by the end of 2026.
Algernon Pharmaceuticals (CSE: AGN, OTCQB: AGNPF), a Canadian clinical-stage pharmaceutical company, has engaged ICP Securities Inc. to provide automated market making services using its proprietary algorithm, ICP Premium™. ICP will be paid CDN $7,500 per month for a three-month initial term, automatically renewing monthly unless canceled with 30 days' notice. ICP will manage supply and demand imbalances of AGNPF shares without third-party funding. Additionally, Algernon has granted 425,000 restricted share units (RSUs) to an employee and a consultant, vesting immediately upon grant and subject to regulatory approval.
FAQ
What is the current stock price of Algernon Pharmac (AGNPF)?
What is the market cap of Algernon Pharmac (AGNPF)?
